BRPI0922100A2 - veiculo de liberação lipossômica não peguilado melhorado, composição terapêutica, método melhorado para tratar um distúrbio do sistema nervoso central, e, composição de diagnóstico. - Google Patents

veiculo de liberação lipossômica não peguilado melhorado, composição terapêutica, método melhorado para tratar um distúrbio do sistema nervoso central, e, composição de diagnóstico.

Info

Publication number
BRPI0922100A2
BRPI0922100A2 BRPI0922100A BRPI0922100A BRPI0922100A2 BR PI0922100 A2 BRPI0922100 A2 BR PI0922100A2 BR PI0922100 A BRPI0922100 A BR PI0922100A BR PI0922100 A BRPI0922100 A BR PI0922100A BR PI0922100 A2 BRPI0922100 A2 BR PI0922100A2
Authority
BR
Brazil
Prior art keywords
treating
nervous system
improved
central nervous
delivery vehicle
Prior art date
Application number
BRPI0922100A
Other languages
English (en)
Inventor
Matthias Luz
Thomas Redelmeier
Original Assignee
Medgenesis Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medgenesis Therapeutix Inc filed Critical Medgenesis Therapeutix Inc
Publication of BRPI0922100A2 publication Critical patent/BRPI0922100A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0023—Di-or triarylmethane dye
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0922100A 2008-11-21 2009-11-23 veiculo de liberação lipossômica não peguilado melhorado, composição terapêutica, método melhorado para tratar um distúrbio do sistema nervoso central, e, composição de diagnóstico. BRPI0922100A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11707608P 2008-11-21 2008-11-21
PCT/CA2009/001708 WO2010057317A1 (en) 2008-11-21 2009-11-23 Liposomal composition for convection-enhanced delivery to the central nervous centre

Publications (1)

Publication Number Publication Date
BRPI0922100A2 true BRPI0922100A2 (pt) 2016-02-10

Family

ID=42197794

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922100A BRPI0922100A2 (pt) 2008-11-21 2009-11-23 veiculo de liberação lipossômica não peguilado melhorado, composição terapêutica, método melhorado para tratar um distúrbio do sistema nervoso central, e, composição de diagnóstico.

Country Status (9)

Country Link
US (1) US9295735B2 (pt)
EP (1) EP2370058B1 (pt)
JP (1) JP5795537B2 (pt)
CN (1) CN102256596B (pt)
AR (1) AR076634A1 (pt)
AU (1) AU2009317837B2 (pt)
BR (1) BRPI0922100A2 (pt)
CA (1) CA2743959C (pt)
WO (1) WO2010057317A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204263D0 (en) * 2012-03-12 2012-04-25 Renishaw Plc Giloma treatment
EP2908909A1 (en) * 2012-10-19 2015-08-26 The Regents Of The University Of California Treating tumors of the central nervous system
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
AU2016206478A1 (en) 2015-01-16 2017-06-15 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
CN109069817B (zh) 2016-04-15 2021-07-13 富士胶片株式会社 微针阵列
EP3603620A4 (en) * 2017-03-31 2020-03-25 FUJIFILM Corporation LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION
US10722465B1 (en) * 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
RU2207808C2 (ru) * 1998-04-09 2003-07-10 Амершем Хелт АС Применение контрастных агентов в форме частиц в диагностической визуализации для изучения физиологических параметров
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
US8518437B2 (en) * 2001-11-13 2013-08-27 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
CN1391891A (zh) * 2002-04-22 2003-01-22 江苏佩沃特生物基因工程有限公司 紫杉醇隐形脂质体
EP1608337A2 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Combination compositions of camptothecins and fluoropyrimidines
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CN100356919C (zh) * 2004-05-31 2007-12-26 上海医药工业研究院 羟基喜树碱脂质体及其制备方法
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
EP2279726A3 (en) * 2005-05-26 2012-06-20 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
CN1823733A (zh) * 2006-01-06 2006-08-30 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
WO2007106549A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for treating brain cancer
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEUROTHERAPY OF HIGH MOLECULAR WEIGHT ENHANCED BY CONVECTION
CN101657189B (zh) 2007-02-13 2014-11-26 康奈尔大学 对流增强型递送装置，方法和应用
US20090209937A1 (en) * 2007-08-11 2009-08-20 Argenis Llc Apparatus and Methods for Treating Epilepsy Using Convection-Enhanced Delivery

Also Published As

Publication number Publication date
EP2370058B1 (en) 2017-10-18
CN102256596A (zh) 2011-11-23
CN102256596B (zh) 2014-10-22
CA2743959A1 (en) 2010-05-27
AR076634A1 (es) 2011-06-29
EP2370058A1 (en) 2011-10-05
JP5795537B2 (ja) 2015-10-14
US20110274625A1 (en) 2011-11-10
AU2009317837A1 (en) 2011-06-30
CA2743959C (en) 2017-09-26
AU2009317837B2 (en) 2016-02-25
JP2012509284A (ja) 2012-04-19
WO2010057317A1 (en) 2010-05-27
US9295735B2 (en) 2016-03-29
EP2370058A4 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
BRPI0922100A2 (pt) veiculo de liberação lipossômica não peguilado melhorado, composição terapêutica, método melhorado para tratar um distúrbio do sistema nervoso central, e, composição de diagnóstico.
BRPI0915383A2 (pt) composto, métodos para tratar um indíviduo que sofre de um distúrbio neurodegenerativo ou psiquiátrico e para tratar um indivíduo que sofre de um vício em droga, e, composição farmacêutica.
BRPI0817664A2 (pt) Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
BRPI0717480A2 (pt) Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto.
BRPI0812740A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
BRPI1011413A2 (pt) sistema, método e marcador luminescente para geração de imagem luminescente difusa melhorada ou tomografia em meio de dispersão
BRPI1012023A2 (pt) método implementado por computador, e métodos para operar um sistema de reservatório e para avaliar um esquema de injeção padrão ou um esquema de injeção periférica.
BRPI0913214A2 (pt) sistema de fornecimento de drogas transdérmico estabilizado
BRPI0816318A2 (pt) Dispositivo de liberação transdérmica, e, método para preparar o mesmo
BRPI0905845A2 (pt) "método, sistema e aparelho para modificação de superfícies"
EP2318088A4 (en) ENSEMBLES AND PORTABLE SYSTEMS FOR PROVIDING FUNCTIONAL OR THERAPEUTIC NEUROSTIMULATION AND ASSOCIATED METHODS
BRPI0819245A2 (pt) sistema de distribuição transdérmica
WO2011053982A3 (en) Therapeutic nuclease compositions and methods
BRPI0921422A2 (pt) sistema de terapia de próstata.
BRPI0917030A2 (pt) sistema de liberação de fármaco contendo progestina
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0822756A2 (pt) sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca.
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI1009004A2 (pt) método para integrar diagnóstico e tratamento para tecidos internos, e, sistema para integrar diagnóstico e tratamento para tecidos internos
EP2305214A4 (en) NEW MOLECULAR ARRANGEMENT, MOLECULAR PROBE FOR MOLECULAR IMAGING AND MOLECULAR PROBE FOR A DRUG DELIVERY SYSTEM, AND MOLECULAR IMAGING SYSTEM AND DRUG DISPENSING SYSTEM
BRPI0818654A2 (pt) Aparelho, sistema e método para estimulação seletiva
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
BRPI0811122A2 (pt) sistema de direcionamento e método para comboio de veículos com rodas.
EP2329810A4 (en) DRUG DISPENSING SYSTEM WITH MAGNETIC RETENTION, MANUFACTURING PROCESS AND APPLICATION
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]